PTEN公司
张力素
髓系白血病
癌症研究
白血病
临床意义
磷酸酶
生物
髓样
病态的
医学
内科学
肿瘤科
细胞凋亡
PI3K/AKT/mTOR通路
酶
生物化学
作者
Ju-Yong Sun,Na Mu,Jia Mu,Wei Li,Zhang Chang-geng,Dongmei Wang
出处
期刊:PubMed
日期:2018-02-01
卷期号:26 (1): 121-125
被引量:2
标识
DOI:10.7534/j.issn.1009-2137.2018.01.020
摘要
To explore the expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) and B-cell lymphoma/leukemia-2 (BCL-2) in acute myeloid leukemia (AML) and its significance.The expression levels of PTEN and BCL-2 mRNA and protein in bone marrow samples from 80 AML patients including 56 de novo patients, 16 patients in remission, 8 relapsed patients and 30 cases of non-hematologic diseases (as control) were detected by real-time PCR and Western blot, respectively, and the relationship between PTEN and BCL-2 expression and clinical pathological parameter was analyzed.The expression levels of both mRNA and protein of PTEN in newly diagnosed AML group and relapse group were significantly lower than those in the control and remission group (P<0.01). The expression levels of both mRNA and protein of BCL-2 in newly diagnosed group and relapse group were significantly higher than those in the control and remission group (P<0.01). The mRNA expression of PTEN and BCL-2 was did not related with the age, sex and white blood count in AML patients. The expression levels of PTEN negatively correlated with expression BCL-2 with AML(r=-0.432, r=-0.569).PTEN and BCL-2 participate in the occurrence and development of AML, and may be used as indicators for the evaluation of chemotheraeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI